Login

Switch On Your HIV Smarts.

Author Archives: Liz Highleyman

New research at CROI 2016: How PrEP changes kidney function

New research at CROI 2016: How PrEP changes kidney function

, by Liz Highleyman

Changes in kidney function with PrEP is not common but may warrant additional screening for people at risk. Read More

New HIV treatments discussed at CROI 2016

New HIV treatments discussed at CROI 2016

, by Liz Highleyman

Long-acting HIV therapy injections and a newer formulation of tenofovir did well in clinical trials. Read More

The U.S. HIV epidemic at CROI 2016: Black gay men have a 1 in 2 lifetime risk

The U.S. HIV epidemic at CROI 2016: Black gay men have a 1 in 2 lifetime risk

, by Liz Highleyman

Studies on epidemiological data highlight disparities in HIV according to race and risk factor. Read More

New European Guidelines Recommend ART for All, PrEP for Those at Risk

New European Guidelines Recommend ART for All, PrEP for Those at Risk

, by Liz Highleyman

European AIDS Clinical Society treatment guidelines align with U.S. recommendations on universal HIV treatment but extend PrEP to non-daily dosing. Read More

Is Dolutegravir Alone Enough to Control HIV?

Is Dolutegravir Alone Enough to Control HIV?

, by Liz Highleyman

Results of studies presented at the European AIDS Conference could lead to simpler, better tolerated, and easier to take regimens for people with difficult-to-treat HIV. Read More